CVS) as the Company's stock will begin trading ex-dividend on October 23, 2017. To capture the dividend payout, investors are required to purchase the stock a day prior (excluding weekend) to the ex-dividend date that is by latest at the end of trading session on October 20, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on CVS. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=CVS

Dividend Declared

On September 19, 2017, CVS Health announced that its Board of Directors has approved a quarterly dividend of $0.50 per share on its common stock. The dividend is payable on November 03, 2017, to holders of record on October 24, 2017.

CVS Health's indicated dividend represents a yield of 2.75%, which is substantially above the average dividend yield of 1.92% for the services sector. The Company has raised dividend for nine consecutive years.

Dividend Insights

CVS Health has a dividend payout ratio of 34.00%, which indicates that the Company distributes approximately $0.34 for every $1.00 earned. The dividend payout ratio reflects how much amount a Company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/ or to add to its cash reserves.

According to analysts' estimates, CVS Health is estimated to report earnings of $6.35 for the next year, which is more than three times the Company's annualized dividend of $2.00 per share.

As of June 30, 2017, CVS Health's cash and cash equivalents totaled $2.09 billion compared to cash of $3.37 billion on December 31, 2016. The Company generated cash flow from operations of $5.53 billion for the six months ended June 30, 2017, compared to $4.09 billion for the year-ago same period and free cash flow of $4.64 billion versus $2.98 billion for the six months ended June 30, 2016. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development for CVS Health

On October 16, 2017, CVS Health and Epic announced a strategic initiative to help lower drug costs for patients and improve outcomes by providing prescribers with expanded visibility to lower cost alternatives through enhanced analytics and data sharing. CVS Health will use Epic's Healthy Planet population health and analytics platform to generate insights surrounding dispensing patterns and behaviors around medication adherence.

The collaboration will bolster prescription decision-making for patients and their care teams, including physicians, pharmacists, and health insurers. Real-time benefit information and facilitated, point-of-prescribing electronic prior authorization will help improve and simplify patient access to necessary medications and ensure their prescribers are aware of prescription insurance formulary status and less expensive alternatives as appropriate.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its 9,700 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.

Stock Performance

At the close of trading session on Thursday, October 19, 2017, CVS Health's stock price marginally rose 0.72% to end the day at $74.63. A total volume of 8.03 million shares were exchanged during the session, which was above the 3-month average volume of 5.55 million shares. The Company's shares are trading at a PE ratio of 14.87 and have a dividend yield of 2.68%. At Thursday's closing price, the stock's net capitalization stands at $77.10 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478349

"/> Dividend Coverage: This Pharmacy Company has a Dividend Yield of 2.75%; Will Trade Ex-Dividend on October 23, 2017 « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

Dividend Coverage: This Pharmacy Company has a Dividend Yield of 2.75%; Will Trade Ex-Dividend on October 23, 2017

LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a closer look at CVS Health Corp. (NYSE: CVS) as the Company's stock will begin trading ex-dividend on October 23, 2017. To capture the dividend payout, investors are required to purchase the stock a day prior (excluding weekend) to the ex-dividend date that is by latest at the end of trading session on October 20, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on CVS. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=CVS

Dividend Declared

On September 19, 2017, CVS Health announced that its Board of Directors has approved a quarterly dividend of $0.50 per share on its common stock. The dividend is payable on November 03, 2017, to holders of record on October 24, 2017.

CVS Health's indicated dividend represents a yield of 2.75%, which is substantially above the average dividend yield of 1.92% for the services sector. The Company has raised dividend for nine consecutive years.

Dividend Insights

CVS Health has a dividend payout ratio of 34.00%, which indicates that the Company distributes approximately $0.34 for every $1.00 earned. The dividend payout ratio reflects how much amount a Company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/ or to add to its cash reserves.

According to analysts' estimates, CVS Health is estimated to report earnings of $6.35 for the next year, which is more than three times the Company's annualized dividend of $2.00 per share.

As of June 30, 2017, CVS Health's cash and cash equivalents totaled $2.09 billion compared to cash of $3.37 billion on December 31, 2016. The Company generated cash flow from operations of $5.53 billion for the six months ended June 30, 2017, compared to $4.09 billion for the year-ago same period and free cash flow of $4.64 billion versus $2.98 billion for the six months ended June 30, 2016. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development for CVS Health

On October 16, 2017, CVS Health and Epic announced a strategic initiative to help lower drug costs for patients and improve outcomes by providing prescribers with expanded visibility to lower cost alternatives through enhanced analytics and data sharing. CVS Health will use Epic's Healthy Planet population health and analytics platform to generate insights surrounding dispensing patterns and behaviors around medication adherence.

The collaboration will bolster prescription decision-making for patients and their care teams, including physicians, pharmacists, and health insurers. Real-time benefit information and facilitated, point-of-prescribing electronic prior authorization will help improve and simplify patient access to necessary medications and ensure their prescribers are aware of prescription insurance formulary status and less expensive alternatives as appropriate.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its 9,700 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.

Stock Performance

At the close of trading session on Thursday, October 19, 2017, CVS Health's stock price marginally rose 0.72% to end the day at $74.63. A total volume of 8.03 million shares were exchanged during the session, which was above the 3-month average volume of 5.55 million shares. The Company's shares are trading at a PE ratio of 14.87 and have a dividend yield of 2.68%. At Thursday's closing price, the stock's net capitalization stands at $77.10 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478349

LONDON, UK / ACCESSWIRE / October 20, 2017 / Pro-Trader Daily takes a closer look at CVS Health Corp. (NYSE: CVS) as the Company's stock will begin trading ex-dividend on October 23, 2017. To capture the dividend payout, investors are required to purchase the stock a day prior (excluding weekend) to the ex-dividend date that is by latest at the end of trading session on October 20, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at:

http://protraderdaily.com/register/

Today, PRO-TD covers ex-dividend news on CVS. Get our free coverage by signing up at:

http://protraderdaily.com/optin/?symbol=CVS

Dividend Declared

On September 19, 2017, CVS Health announced that its Board of Directors has approved a quarterly dividend of $0.50 per share on its common stock. The dividend is payable on November 03, 2017, to holders of record on October 24, 2017.

CVS Health's indicated dividend represents a yield of 2.75%, which is substantially above the average dividend yield of 1.92% for the services sector. The Company has raised dividend for nine consecutive years.

Dividend Insights

CVS Health has a dividend payout ratio of 34.00%, which indicates that the Company distributes approximately $0.34 for every $1.00 earned. The dividend payout ratio reflects how much amount a Company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/ or to add to its cash reserves.

According to analysts' estimates, CVS Health is estimated to report earnings of $6.35 for the next year, which is more than three times the Company's annualized dividend of $2.00 per share.

As of June 30, 2017, CVS Health's cash and cash equivalents totaled $2.09 billion compared to cash of $3.37 billion on December 31, 2016. The Company generated cash flow from operations of $5.53 billion for the six months ended June 30, 2017, compared to $4.09 billion for the year-ago same period and free cash flow of $4.64 billion versus $2.98 billion for the six months ended June 30, 2016. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain its dividend distribution for a long period.

Recent Development for CVS Health

On October 16, 2017, CVS Health and Epic announced a strategic initiative to help lower drug costs for patients and improve outcomes by providing prescribers with expanded visibility to lower cost alternatives through enhanced analytics and data sharing. CVS Health will use Epic's Healthy Planet population health and analytics platform to generate insights surrounding dispensing patterns and behaviors around medication adherence.

The collaboration will bolster prescription decision-making for patients and their care teams, including physicians, pharmacists, and health insurers. Real-time benefit information and facilitated, point-of-prescribing electronic prior authorization will help improve and simplify patient access to necessary medications and ensure their prescribers are aware of prescription insurance formulary status and less expensive alternatives as appropriate.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its 9,700 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 90 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.

Stock Performance

At the close of trading session on Thursday, October 19, 2017, CVS Health's stock price marginally rose 0.72% to end the day at $74.63. A total volume of 8.03 million shares were exchanged during the session, which was above the 3-month average volume of 5.55 million shares. The Company's shares are trading at a PE ratio of 14.87 and have a dividend yield of 2.68%. At Thursday's closing price, the stock's net capitalization stands at $77.10 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 478349

Source URL: https://marketersmedia.com/dividend-coverage-this-pharmacy-company-has-a-dividend-yield-of-2-75-will-trade-ex-dividend-on-october-23-2017/253038

Source: AccessWire

Release ID: 253038


Latest News